Skip to main content
Go to the home page of the European Commission (opens in new window)
English en
CORDIS - EU research results
CORDIS

AI-assisted peRsonalized heart-on-chIp as advanced diagnostic Tool for clinical significance assessMent of Inherited cArdiomyopathies

Project description

AI-assisted diagnostic tool for inherited cardiomyopathies

Inherited cardiomyopathies (iCMPs) contribute to heart disease and deaths in young patients. Despite advances in sequencing, fewer than 50 % of pathogenic variants are identified, leaving many novel variants of uncertain significance (VUS) that complicate diagnosis and treatment decisions. The EIC-funded AI-RITMIA project aims to link specific VUSs to CMP phenotypes by creating an AI-guided heart-on-chip diagnostic tool. This tool will integrate patient-specific modelling, AI data analysis, and clinical evaluation to provide clinicians with actionable pathogenicity scores. Key resources include in vitro models, patient-specific stem cells, a large CMP patient cohort, and AI data interfaces from various consortium partners.

Objective

Inherited cardiomyopathies (iCMPs) are a major causeInherited cardiomyopathies (iCMPs) are a major cause of heart disease and account for a significant percentage of deaths in young patients. While recent advances in next-generation sequencing have enabled testing of a large number of genes related to iCMPs, the rate of identification of pathogenic variants is still below 50%. On the other hand, this unprecedented sequencing power has led to an exponential increase in detecting novel unclassified genetic variants (VUS), for which pathogenicity has not been confirmed. VUS uncertainty of diagnosis poses important problems in clinical evaluations, therapeutic decisions and risk-assessment both for patient and family members.
The AI-RITMIA Consortium proposes a breakthrough innovation to establish a conclusive link between specific VUSs and CMP
clinical phenotypes, yielding to the development of an unprecedented technological platform: a radically new AI-guided patient-specific heart-on-chip diagnostic tool (AI-RITMIA) will be able to interface for the first time three currently diverging sectors: patient specific in vitro modelling, in silico and artificial intelligence (AI) based data handling and clinical evaluation. AI-RITMIA will be the first clinical grade personalized in vitro-in silico platform enabling faster and unbiased correlations of clinical outcomes with functional in vitro profiling for VUS-carrying patients, returning a pathogenicity score directly to the clinicians to unlock informed diagnosis and therapeutic decisions. The achievement of such innovation will leverage on enabling technologies and resources uniquely available in the Consortium, which brings together excellences from the three interfacing worlds: 1) in vitro models based on OoC and microsensors @POLIMI, @BIOMIMX, @NMI and patient-specific iPSCs @ICH; 2) the largest EU cohort of well characterized CMP patients @COCHIN, and 3) clinical grade AI-based data handling interfaces @TUM, @ADVICE.

Fields of science (EuroSciVoc)

Keywords

Programme(s)

Topic(s)

Funding Scheme

HORIZON-EIC - HORIZON EIC Grants

See all projects funded under this funding scheme

Call for proposal

(opens in new window) HORIZON-EIC-2025-PATHFINDEROPEN

See all projects funded under this call

Coordinator

POLITECNICO DI MILANO
Net EU contribution
€ 682 500,00
Address
PIAZZA LEONARDO DA VINCI 32
20133 Milano
Italy
Region
Nord-Ovest Lombardia Milano
Activity type
Higher or Secondary Education Establishments
Links
Total cost
€ 682 500,00

Participants (6)